Related Experiment Video
Updated: May 25, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Advanced glycation end products and diabetic cardiovascular disease
Anand Prasad1, Peter Bekker, Sotirios Tsimikas
1Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. anandprasadmd@gmail.com
Abstract:
Advanced glycation end products (AGEs) are formed by a nonenzymatic reaction of sugar moieties (eg, glucose, fructose, glycolytic adducts) with the free amino groups on amino acid residues of proteins. A growing body of data demonstrate that AGEs are intimately involved in the pathophysiology of cardiovascular disease by stimulating inflammation, contributing to atheroma formation, and modulating vascular stiffness. The role of AGEs as potential biomarkers for disease presence and prognosis in patients with diabetes mellitus remains an active area of study. Epidemiologic and angiographic studies suggest that AGE levels may be related to the presence and extent of atherosclerosis, and may predict future outcomes in select populations. The present review summarizes the relevant evidence supporting the role of advanced glycation in promoting atherosclerosis and the epidemiologic studies demonstrating an association between AGEs and diabetic cardiovascular disease.
Related Concept Videos
Diabetic Nephropathy
Diabetic Neuropathy
Coronary Artery Disease I: Introduction
Diabetic Retinopathy
Complications of Diabetes Mellitus
Diabetes Mellitus: Type 2 and Gestational